Doxepin chemical structure
Find information on thousands of medical conditions and prescription drugs.

Doxepin

Doxepin is a tricyclic antidepressant, known under many brand-names such as Aponal®, the original preparation by Boehringer-Ingelheim, now part of the Roche group; Adapine®, Sinquan® and Sinequan® (Pfizer Inc.); and Zonalon®, a cream-based preparation. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Pharmacology

Doxepin inhibits the reuptake of serotonin and noradrenaline from the synaptic cleft (dual action). The reuptake-inhibition of dopamine is very weak.

It has antagonistic effects (blockade) on a variety of postsynaptic receptors:

  • Extremely strong : H1, H2
  • Strong : 5-HT2, Alpha1, Muscarinic
  • Moderate : 5-HT1
  • Weak : D2, Alpha2

These effects account for the actions as well for most side-effects (sedation, hypotension, anticholinergic side-effects, massive weight gain). Doxepin shows strong antagonism against the effects of Reserpin (amine depletion) in the animal model. Like other 'classical' antidepressants it has a sodium channel blocking activity, possibly accounting for its analgesic action. Additionally, Doxepin exerts a strong local-anesthetic action.

Peak plasma levels are seen 2 to 3 hours after oral dosing.

Toxicology

acute toxicity:

  • Mouse : i.v. 15 - 20mg/kg body weight, oral 148 - 178mg/kg body weight
  • Rat : i.v. 13 - 19mg/kg body weight, oral 346 - 460mg/kg body weight
  • Human : Not exactly known, clinical experience indicates a rather high acute toxicity, as is the case with other tri-/tetracyclics. Fatal dose in sensitive adults may be as low as 500 to 1,000mg oral (7 to 14mg/kg). In children below 12 yrs. of age any oral intake is to be considered as serious.

chronic toxicity

  • Dog and Rat : Fat deposits in liver cells and decrease of triglyceride levels in plasma
  • Human : Data not available

Indications

Approved uses may vary by country. In the United States, the only FDA approved use of doxepin is the treatment of depression. All other uses should be considered off-label.

  • Depression
  • Anxiety disorder, longterm-treatment is possible
  • Insomnia, also suitable for longterm-treatment
  • Alleviation of the symptoms of alcohol and drug withdrawal (N.B.: Doxepin does not suppress seizure activity in alcoholics ('rum fits'). Cotreatment with benzodiazepines or barbiturates is needed to treat seizures effectively.)
  • Gastrointestinal ulceration and other GI-problems (e.g. irritable bowel syndrome), whether part of depression or not. The action is due to strong H2-receptor antagonism. The efficiacy is comparable to H2-Receptor-Inhibitors.
  • Chronic pain, particular tension headaches, whether associated with depression or not
  • External treatment of itching skin disease with Zonalon®

Contraindications

absolute :

  • known hypersensitivity to doxepin or other dibenzoxepines or other ingredients of the drug
  • acute intoxication with alcohol, sedatives, analgesics and other psychoactive drugs
  • acute delirium tremens
  • untreated closed angle glaucoma
  • hypertrophy of the prostate with urine retention
  • paralytic ileus

relative :

Read more at Wikipedia.org


[List your site here Free!]


Vestibular ENG findings in a 46-year-old woman with dizziness and an autoimmune disease
From Ear, Nose & Throat Journal, 8/1/05 by Kenneth H. Brookler

A 46-year-old woman presented with a chief complaint of dizziness, which had begun approximately 16 years earlier and had recurred 8 or 9 times. Her spells lasted from a day up to a few weeks. The first episode was associated with food allergy. She described the sensation as a feeling that she was being pulled to the right; during these episodes, she did not feel well and she noted a decrease in her ability to concentrate and a problem with her memory. She said she sometimes felt as if the floor were only 16 inches away. In terms of balance, she likened herself to a puppet on a string being pulled to the right. During the previous week, she had experienced a spell of room-spinning while she was smoking a cigarette. Some of her symptoms were triggered by exercising and were intensified when she had taken doxepin.

The patient was occasionally sensitive to loud sound, but she reported no subjective hearing loss. During the preceding 2 weeks, tinnitus had occurred twice; each episode had lasted a few minutes. The tinnitus was equal in both ears, and she described it as "white-noise sound" or "empty-room sound." She reported no aural fullness or headaches. She had recently been diagnosed with an autoimmune disease, and she was taking prednisone and doxepin. She had also been on thyroid hormone replacement therapy for 2 years for the treatment of Graves' disease and the hypothyroidism associated with it. There was a family history of dizziness (her mother) and hearing loss (her father). Clinical examination revealed an inability to perform the Romberg's test.

Electronystagmography detected a 5[degrees]/sec left-beating spontaneous nystagmus. Elements of the nystagmus as seen on simultaneous recordings revealed a central dysrhythmic pattern. The alternate binaural bithermal (ABB) caloric test, when corrected for the preexisting nystagmus, did not induce any left-beating nystagmus. This test revealed a 100% directional preponderance to the right and no significant reduced vestibular response.

The simultaneous binaural bithermal (SBB) test showed only the preexisting spontaneous nystagmus, and therefore there was no caloric-induced response to either the cool or warm simultaneous stimulus. Findings on audiometry were normal, and contrast-enhanced magnetic resonance imaging (MRI) was negative.

This case illustrates the ability of electronystagmography to demonstrate a vestibular abnormality. An abnormal vestibular system was made evident by the spontaneous nystagmus during the ABB test. A failure to correct for preexisting nystagmus during caloric tests might have suggested misleading diagnostic possibilities. Taking the correction into consideration, the SBB test did not add any useful diagnostic information. The MRI had ruled out a pathologic central nervous system disorder, and the medical diagnosis suggested an autoimmune basis for her symptoms.

COPYRIGHT 2005 Medquest Communications, LLC
COPYRIGHT 2005 Gale Group

Return to Doxepin
Home Contact Resources Exchange Links ebay